Evidence map›Paper›PMID 41713138›Full record

ArticleMolecular genetics and metabolism2026

Albumin as a glycoprotein biomarker in congenital disorders of glycosylation.

Kishore Garapati, Anu Jain, Neha Joshi, Gunveen S Sachdeva, Dowoon Nam, Mayank Saraswat, Raghavendra Rao Pasupuleti, Matthew J Schultz, Tamas Kozicz, Eva Morava and 1 more

Abstract read
In one paragraph

Article in Molecular genetics and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kishore GarapatiManipal Academy of Higher Education (MAHE), Manipal, Karnataka, India; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Anu JainDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Neha JoshiDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Gunveen S SachdevaManipal Academy of Higher Education (MAHE), Manipal, Karnataka, India; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA; Institute of Bioinformatics, International Technology Park, Bangalore, Karnataka, India.
Dowoon NamDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Mayank SaraswatDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Raghavendra Rao PasupuletiDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Matthew J SchultzBiochemical Genetics Laboratory, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Tamas KoziczBiochemical Genetics Laboratory, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA; Department of Clinical Genomics, Mayo Clinic, Rochester, MN, USA; Department of Genomics and Genetic Sciences, Ichan School of Medicine at Mount Sinai Hospital, New York, NY, USA.
Eva MoravaBiochemical Genetics Laboratory, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA; Department of Clinical Genomics, Mayo Clinic, Rochester, MN, USA; Department of Genomics and Genetic Sciences, Ichan School of Medicine at Mount Sinai Hospital, New York, NY, USA.
Akhilesh PandeyDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA; Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA. Electronic address: pandey.akhilesh@mayo.edu.

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Lila J. Rutten · 1985 to 2026
$151.3M
Pilot and Feasibility CoreU54NS115198 · NINDS · MAYO CLINIC ROCHESTER · PI MORAVA-KOZICZ, EVA · 2019 to 2023
$8.2M
Mayo Clinic Center for Clinical ProteomicsU01CA271410 · NCI · MAYO CLINIC ROCHESTER · PI Rafael Fonseca, AKHILESH PANDEY · 2022 to 2026
$5.3M
NCI NIH HHS P30 CA015083NCI NIH HHS U01 CA271410NINDS NIH HHS U54 NS115198Wellcome Trust
6 · The paper itself

Abstract

Congenital disorders of glycosylation (CDG) are rare inherited disorders resulting from defects in cellular glycosylation machinery. Albumin has recently been shown to be N-glycosylated at two non-canonical glycosylation sites. We applied multiplexed mass spectrometry-based glycoproteomics to identify site-specific N-glycosylation alterations in albumin from patients with PMM2-CDG, MPI-CDG, SRD5A3-CDG, MAN1B1-CDG and PGM1-CDG. Our findings demonstrate that the glycosylation of albumin is indeed affected in CDG and indicate a potential role for albumin-derived glycopeptides as diagnostic biomarkers.

Indexed as

Congenital Disorders of GlycosylationGlycoproteinsSerum AlbuminBiomarkersGlycopeptidesGlycosylationHumansMass SpectrometryProteomicsBiomarkersGlycopeptidesGlycoproteinsSerum AlbuminBlood-based biomarkersGenetic disordersGlycosylationHSARare disease diagnosis

Identifiers

PMID41713138
PMCPMC13051346

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.